```
=> d
L1 HAS NO ANSWERS
L1                STR
```



```
Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 13:49:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    147 TO ITERATE

100.0% PROCESSED     147 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          2213 TO     3667
PROJECTED ANSWERS:                0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 13:49:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   2749 TO ITERATE

100.0% PROCESSED    2749 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01

L3             4 SEA SSS FUL L1

=> s l3 and caplus/lc
      19066955 CAPLUS/LC
L4             3 L3 AND CAPLUS/LC

=> s l3 not l4
```

L5 1 L3 NOT L4

=> d

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN 135804-08-9 REGISTRY
CN Octadecanamide, N-[2-hydroxy-3-(phosphonooxy)propyl]- (9CI) (CA
INDEX
NAME)
FS 3D CONCORD
MF C21 H44 N O6 P
CI COM
SR CA



```
=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              139.48     139.63

FILE 'CAPLUS' ENTERED AT 13:50:15 ON 24 SEP 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1947 - 24 Sep 2001  VOL 135 ISS 14
FILE LAST UPDATED: 23 Sep 2001  (20010923/ED)
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.


```
*** YOU HAVE NEW MAIL ***

=> s l3
L6            3 L3

=> d ibib abs hitstr 1-3
```

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2001 ACS (Continued)



CM 2

CRN 141-43-5
CMF C2 H7 N O

```
=> fil beil
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    14.85     154.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.76      -1.76

FILE 'BEILSTEIN' ENTERED AT 13:54:13 ON 24 SEP 2001
COPYRIGHT (c) 2001 Beilstein-Institut zur Foerderung der Chemischen
Wissenschaften licensed to Beilstein Chemiedaten & Software GmbH and MDL
Information Systems GmbH

FILE LAST UPDATED: 6 MAR 2000

FILE COVERS 1779 TO 2000.
*** CAS REGISTRY NUMBERS FOR 4,356,237 SUBSTANCES AVAILABLE ***
*** FILE CONTAINS 7,688,486 SUBSTANCES ***

**********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.                *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE   *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE          *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                        *
* FOR PRICE INFORMATION SEE HELP COST                                *
**********************************************************************


*** YOU HAVE NEW MAIL ***

=> s l1 ful

FULL SEARCH INITIATED 13:54:18 FILE 'BEILSTEIN'
FULL SCREEN SEARCH COMPLETED -    363 TO ITERATE

100.0% PROCESSED     363 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.04

L7            0 SEA SSS FUL L1

=> fil marpat
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.00     154.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.76

FILE 'MARPAT' ENTERED AT 13:54:29 ON 24 SEP 2001
```

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE CONTENT: 1988-PRESENT (VOL 104 ISS 15-VOL 135 ISS 13) (20010921/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 200101623 23 AUG 2001
DE 10105944 23 AUG 2001
EP 1127868 29 AUG 2001
JP 200124052 04 SEP 2001
WO 200106276 30 AUG 2001

MARPAT structure search limits have been raised.
Enter HELP SLIMIT for details.

*** YOU HAVE NEW MAIL ***

=> s l1 ful
FULL SEARCH INITIATED 13:54:34 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 1670 TO ITERATE

100.0% PROCESSED 1670 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.12

L8 8 SEA SSS FUL L1

=> d ibib abs fqhit 1-8

L8 ANSWER 1 OF 8 MARPAT COPYRIGHT 2001 ACS
ACCESSION NUMBER: 133:329624 MARPAT
TITLE: Compositions and methods for treating amyloidosis
INVENTOR(S): Gordon, Heather; Szarek, Walter; Weaver, Donald; Kong, Xianqi
PATENT ASSIGNEE(S): Queen's University at Kingston, Can.; Neurochem, Inc.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064420	A2	20001102	WO 2000-CA494	20000428
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-131464 19990428
US 1999-135545 19990524
US 1999-143123 19990709

AB Therapeutic compds. and methods for modulating amyloid aggregation in a subject, whatever its clin. setting, are described. Amyloid aggregation is modulated by the administration to a subject of an effective amt. of a therapeutic compd. [(R1Zk)(R2Qm)N]pTYs [R1, R2 = H, (un)substituted alkyl, (un)substituted aryl; Z, Q = C(O), C(S), SO2, SO; k, m = 0, 1, with provisions; p, s = pos. integer such that biodistribution of therapeutic compd. for intended target site is not prevented while maintaining activity of therapeutic compd.; T = linking group; Y = AX; A = anionic

L8 ANSWER 1 OF 8 MARPAT COPYRIGHT 2001 ACS (Continued)
group at physiol. pH; X = cationic group], or a pharmaceutically acceptable salt or ester, such that modulation of amyloid aggregation occurs. Prepn. of e.g. 8-methoxy-5-quinolinesulfonic acid sodium salt is described.

MSTR 1



G1 = 23



G7 = 275-1 277-3



G8 = OPO3H2
G12 = COMe
MPL: claim 1

L8 ANSWER 2 OF 8 MARPAT COPYRIGHT 2001 ACS
ACCESSION NUMBER: 130:276756 MARPAT
TITLE: Novel osteoblast-specific mitogens for treatment of metabolic disorders of bone
INVENTOR(S): Esswein, Angelika; Kling, Lothar
PATENT ASSIGNEE(S): Roche Diagnostics G.m.b.H., Germany
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 906759	A1	19990407	EP 1997-117124	19971002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 9917781	A1	19990415	WO 1998-EP6214	19980930
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9911483	A1	19990427	AU 1999-11483	19980930
EP 1019062	A1	20000719	EP 1998-954302	19980930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
BR 9813020	A	20000815	BR 1998-13020	19980930
US 6197759	B1	20010306	US 2000-508714	20000411

PRIORITY APPLN. INFO.: EP 1997-117124 19971002
WO 1998-EP6214 19980930

AB Lysophosphatidic acid derivs. R1(CH2)nCH2C(O)XCH2CH(OH)CH2OP(O)(OH)2 [R1 = C6-24 alkyl, alkenyl, alkynyl; X = O, NH; n = 0-12] stimulate bone formation and are useful for treatment of various metabolic disorders of bone such as osteoporosis. Thus, exposure of primary osteoblasts from fetal rat calvaria to 2-hydroxy-3-phosphonooxypropyl L-.alpha.-cis-9-octadecenoate (I) for 24 h stimulated DNA formation to 253% of the control value. I was prepd. in 7 steps from oleoyl chloride and

L8 ANSWER 2 OF 8 MARPAT COPYRIGHT 2001 ACS (Continued)
2,2-dimethyl-4-hydroxymethyldioxolane.

MSTR 1



G3 = NH
DER: and physiologically acceptable salts and esters and derivatives
MPL: claim 1
STE: and optically active forms and racemates

REFERENCE COUNT: 7
REFERENCE(S): (1) Cao, Y; PLANT PHYSIOL 1990, V94(3), P1199 CAPLUS
(2) Laboratorios Menarini S A; WO 9428004 A CAPLUS
(3) Moolenaar, W; JOURNAL OF BIOLOGICAL CHEMISTRY 1995, V270(22), P12949 CAPLUS
(4) Ortho Pharmaceutical Corp; EP 0524023 A CAPLUS
(5) Siddiqui, R; CELL SIGNALLING 1996, V8(5), P349 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 8 MARPAT COPYRIGHT 2001 ACS
ACCESSION NUMBER: 130:52675 MARPAT
TITLE: Preparation of anionic glycasuccinamide as surfactants
INVENTOR(S): Au, Van; Vermeer, Robert; Harichian, Bijan
PATENT ASSIGNEE(S): Lever Brothers Company, USA
SOURCE: U.S., 44 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5844103	A	19981201	US 1995-410198	19950324
US 5786468	A	19980728	US 1997-909374	19970811
PRIORITY APPLN. INFO.:			US 1995-410198	19950324

AB Anionic glycasuccinamides ACO(CH2)cCH(CO2A1)W[(CHX)dY]eZR (A = sugar, A1 = H, alkali, alk., amino acid, ammonium, alkyl; W = CH2, O; X = H, alkyl; Y = substituted amine, O, S, SO2, CO2, amide; Z = CH:CH, CH2CH2; R = hydrocarbon, c = 1-3, d = 1-5, e = 0-35) were prepd. as surfactants. Thus, sodium dodecyl Me D-glucosuccinimide was prepd. as surfactant (Kraft point Tk < 0.degree.).

MSTR 1



G1 = (1-3) CH2
G7 = 181



L8 ANSWER 3 OF 8 MARPAT COPYRIGHT 2001 ACS (Continued)

G8 = (1-6) 21

G9 = OH / 23

G10 = PO3H2
G23 = NH
DER: or metal or ammonium salts
MPL: claim 1
NTE: also incorporates broader disclosure

REFERENCE COUNT: 27
REFERENCE(S): (4) Anon; EP 550278 1993 CAPLUS
(5) Anon; EP 550281 1993 CAPLUS
(6) Au; US 5296588 1994 CAPLUS
(7) Au; US 5310542 1994 CAPLUS
(8) Au; US 5336765 1994 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 8 MARPAT COPYRIGHT 2001 ACS
ACCESSION NUMBER: 129:280999 MARPAT
TITLE: Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
INVENTOR(S): Bathurst, Ian C.; Foehr, Matthew W.; Goddard, J. Graham; Vmansky, Samuil R.; Bradley, John D.; Picker, Donald H.
PATENT ASSIGNEE(S): LXR Biotechnology Inc., USA
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9841213	A1	19980924	WO 1998-US5325	19980318
W: AL, AM, AT, AU, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9865650	A1	19981012	AU 1998-65650	19980318
EP 1024812	A1	20000809	EP 1998-911776	19980318
R: CH, DE, FR, GB, IT, LI, NL				
PRIORITY APPLN. INFO.:			US 1997-39376	19970319
			US 1997-39379	19970319
			US 1997-39380	19970319
			US 1997-56120	19970820
			WO 1998-US5325	19980318

AB The present invention provides therapeutic compns. contg. lysophosphatidic acids (LPA), methods for making the compns., and methods of use thereof. The compns. comprising LPA and a potentiating component, exhibit anti-apoptosis activity and preserve or restore functions of cells, tissues, and organs. The present invention specifically encompasses 3-O-oleoyl-2-O-methylglycero-1-thiophosphate, oleyl 1-thiophosphoryl-2-O-methylglycerate, 3-O-oleyl-2-O-methylglycero-1-thiophosphate, and salts thereof.

MSTR 3

L8 ANSWER 4 OF 8 MARPAT COPYRIGHT 2001 ACS (Continued)

G1 = 2

G2 = 3



G3 = 10

G4 = OH
G7 = O
G8 = (0-10) CH2
G9 = undecyl
G15 = OH
DER: or pharmaceutically acceptable salts
MPL: claim 14
NTE: substitution is restricted

L8 ANSWER 5 OF 8 MARPAT COPYRIGHT 2001 ACS
ACCESSION NUMBER: 129:161813 MARPAT
TITLE: Preparation of anionic glycasuccinamide as surfactant
INVENTOR(S): Au, Van; Vermeer, Robert; Harichian, Bijan
PATENT ASSIGNEE(S): Lever Brothers Company, Division of Conopco, Inc., USA
SOURCE: U.S., 39 pp. Division of U.S. Ser. No. 410.198.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5786468	A	19980728	US 1997-909374	19970811
US 5844103	A	19981201	US 1995-410198	19950324

PRIORITY APPLN. INFO.: US 1995-410198 19950324
AB Alkyl and alkenyl anionic glycasuccinamides RCOCH[(CH2)cCO2R1]O[(CHX)aY]bZ R2 (R = sugar, residue; R1 = H, alkali metal, alk. earth metal, ammonium, alkyl substituted ammonium, alkanolammonium ; X = H, alkyl; Y = amine, O, S, SO, SO2, CO2, amide; Z = CH:CH, CH2CH2, R2 = hydrocarbon, aryl; a = 1-5; b = 0-35; c = 1-3) were prepd. as surfactants. Thus, decyl Me D-glucosuccinamide was prepd. and the temp. a which the surfactant ppts. out of soln. upon cooling was taken as the Krafft point (Tk < 0.degree., 0.1%). Title compds. are readily sol. in water and form micelles at low temps.

MSTR 1



G1 = (1-3) CH2

L8 ANSWER 5 OF 8 MARPAT COPYRIGHT 2001 ACS (Continued)
G7 = 181



G8 = (1-6) 21

G9 = OH / 23

G10 = PO3H2
G23 = NH
DER: or metal or ammonium salts
MPL: claim 1
NTE: also incorporates broader disclosure

L8 ANSWER 6 OF 8 MARPAT COPYRIGHT 2001 ACS
ACCESSION NUMBER: 126:203707 MARPAT
TITLE: Phospholipids as mineral absorption promoters and compositions containing mineral absorption promoters
INVENTOR(S): Tsuji, Kunio; Nakamura, Teruo; Inaoka, Yasunori
PATENT ASSIGNEE(S): Tsuji Kunio, Japan; Higashishizuoka Yakuruto Hanba; Pola Kasei Kogyo Kk
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09020676	A2	19970121	JP 1995-167670	19950703

AB Phospholipids preferably dipalmitoylphosphatidylethanolamine as mineral absorption promoters and mineral supplement compns. contg. mineral absorption promoters are claimed. In rats, dipalmitoylphosphatidylethanol amine markedly enhanced the Ca absorption compared to controls. Mineral promoter granules were formulated contg. cryst. cellulose 40, starch 20, lactose 20, dipalmitoylphosphatidylethanolamine 10 and hydroxypropyl cellulose 10 parts.

MSTR 1



G1 = O / NH
G3 = OH
G4 = 15

L8 ANSWER 6 OF 8 MARPAT COPYRIGHT 2001 ACS (Continued)

G5 = pentadecyl
G8 = OH
MPL: claim 1

L8 ANSWER 7 OF 8 MARPAT COPYRIGHT 2001 ACS
ACCESSION NUMBER: 124:135725 MARPAT
TITLE: Cell signaling inhibitors
INVENTOR(S): Michnick, John; Underiner, Gail E.; Klein, J. Peter;
Rice, Glenn C.
PATENT ASSIGNEE(S): Cell Therapeutics, Inc., USA
SOURCE: U.S., 82 pp. Cont.-in-part of U.S. Ser. No. 40,820,
abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5470878	A	19951128	US 1993-164081	19931208
WO 9422863	A1	19941013	WO 1994-US3548	19940331
W: AU, BR, CA, CH, CN, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2159640	AA	19941013	CA 1994-2159640	19940331
AU 9465538	A1	19941024	AU 1994-65538	19940331
AU 695674	B2	19980820		
ZA 9402317	A	19950210	ZA 1994-2317	19940331
CN 1122600	A	19960515	CN 1994-191983	19940331
CN 1040980	B	19981202		
EP 719267	A1	19960703	EP 1994-913336	19940331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CH 686830	A	19960715	CH 1994-3711	19940331
JP 08508981	T2	19960924	JP 1994-522380	19940331
US 5641783	A	19970624	US 1994-302842	19940908
US 5750575	A	19980512	US 1995-475721	19950607
US 5777117	A	19980707	US 1995-472569	19950607
US 5824677	A	19981020	US 1995-474816	19950607
AU 9890518	A1	19990114	AU 1998-90518	19981104

PRIORITY APPLN. INFO.: US 1993-40820 19930331
US 1993-152650 19931112
US 1993-164081 19931208
AU 1994-65538 19940331
WO 1994-US3548 19940331
US 1994-303842 19940908

GI

L8 ANSWER 7 OF 8 MARPAT COPYRIGHT 2001 ACS (Continued)



I



II

AB Therapeutic compds. have the formula: (X)j-(non-cyclic core moiety), j = 1-3, the core moiety is non-cyclic, and X is a racemic mixt., R or S enantiomer, solvate, hydrate, or salt of, R1R2(CH2)rCH(OR3)(CH2)sR, r = 1-4 [one or more carbon atoms of (CH2)r may be substituted by a keto or hydroxy group], and s = 1-14. Independently, R1 and R2 may be a hydrogen, a straight or branched chain alkane or alkene of up to 12 carbon atoms in length, or --(CH2)wR5, w = 2-14, and R5 = mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R5 being hydroxy, chloro, fluoro, bromo, or C1-6 alkoxy. Or jointly, R1 and R2 form a substituted or unsubstituted, satd. or unsatd. heterocyclic group having from 4-8 carbon atoms, N being a hetero atom. R3 is a hydrogen or C1-3. Therapeutic compds. may also be I where R4 is hydrogen, a straight or branched chain alkane or alkene of up to eight carbon atoms in length, --(CH2)wR5, w = 2-14 and R5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R5 being hydroxy, chloro, fluoro, bromo, or C1-6 alkoxy, or a substituted or unsubstituted, satd. or unsatd. heterocyclic group having from 4-8 carbon atoms; m and n are independently integers from 1-4, the sum (m+n) not being greater than 5; p = 1-14 and one or more carbon atoms of (CH2)n or (CH2)p may be substituted by a keto or hydroxy group. Effects of these agents on various biochem. parameters (immunomodulation, cytokines and interleukins, etc.) were examd. and results presented. As an example, I inhibited PDGF-induced proliferation of aortic smooth muscle cells.

MSTR 2A



G15—G5

G2 = (1-4) 7

G3

G4 = (1-14) CH2
G5 = OPO3H2 (SO)
G9 = 15

G10

G10 = COMe
G15 = 4

G22

G22 = OH
GGA = 9 <EC (1-4) C, BD (ALL) SE, DC (0) M3>
DER: or solvates, hydrates or salts
MPL: disclosure
NTE: substitution is restricted
STE: racemates or R or S enantiomers

L8 ANSWER 8 OF 8 MARPAT COPYRIGHT 2001 ACS
ACCESSION NUMBER: 115:64809 MARPAT
TITLE: Angiogenic monobutyrin and its analogs
INVENTOR(S): Spiegelman, Bruce M.; Castellot, John J., Jr.; Dobson, Deborah E.
PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, USA; Harvard College
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9011075	A1	19901004	WO 1990-US1564	19900322
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
US 5137734	A	19920811	US 1989-327314	19890322
AU 9054146	A1	19901022	AU 1990-54146	19900322

PRIORITY APPLN. INFO.: US 1989-327314 19890322
WO 1990-US1564 19900322

AB Angiogenesis is stimulated by administering an angiogenic glyceride CH2(XR1)CH(OR1)CH(OR2)CH2OR3 (I) or CH2(OR2)CH(XR1)CH2OR3 (II) [X = O, NH, S, CH2; R1 = (substituted) C2-10 alkyl or acyl; R2, R3 = H, PO32-, R1; or, in I, R2 and R3 together are alkylene or OR2 and OR3 form an epoxide]. I, II or mixts. can be used in combination with various peptide growth factors to enhance the angiogenic effect. An angiogenic factor was isolated from conditioned 3T3 adipocyte medium and identified as monobutyrin [i.e., I; X = O; R2, R3 = H; R1 = CH3(CH2)2C:O]. Monobutyrin and basic fibroblast growth factor (FGF) behaved in a synergistic manner in the chick chorioallantoic membrane assay. Control, contg. only buffer (0.9% NaCl) elicited 9% pos. responses. Monobutyrin at 34 pg/pellet yielded 24% pos. responses; basic FGF at 1 ng/pellet yielded 15% pos. responses; the combination gave 72% pos. responses. An ointment contained monocaprylin 0.1, polyethylene 0.5, and heavy mineral oil 95.0 g.

MSTR 1A

L8 ANSWER 8 OF 8 MARPAT COPYRIGHT 2001 ACS (Continued)



G1 = NH
G2 = 20

G5 = OH / 10

G6 = 10

G8 = (0-8) CH2
MPL: claim 1

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	125.10	279.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.48	-6.24

* *

Dear valued customer,

Your feedback is important to us. Would you kindly take a moment to complete our survey? This survey will only take about 5-10 minutes to complete. Your responses will be kept confidential and will help us improve STN Express with Discover! for your future use. Please click on the following link to access the survey.

http://www.cas.org/ONLINE/STN/ExpressSurveyForm.html?LOGINID=SSSPTA1201LXS

* *

STN INTERNATIONAL LOGOFF AT 13:55:49 ON 24 SEP 2001

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:241996 CAPLUS
DOCUMENT NUMBER: 130:276756
TITLE: Novel osteoblast-specific mitogens for treatment of
metabolic disorders of bone
INVENTOR(S): Esswein, Angelika; Kling, Lothar
PATENT ASSIGNEE(S): Roche Diagnostics G.m.b.H., Germany
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 906759	A1	19990407	EP 1997-117124	19971002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 9917781	A1	19990415	WO 1998-EP6214	19980930
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9911483	A1	19990427	AU 1999-11483	19980930
EP 1019062	A1	20000719	EP 1998-954302	19980930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
BR 9813020	A	20000815	BR 1998-13020	19980930
US 6197759	B1	20010306	US 2000-508714	20000411

PRIORITY APPLN. INFO.: EP 1997-117124 A 19971002
WO 1998-EP6214 W 19980930
OTHER SOURCE(S): MARPAT 130:276756
AB Lysophosphatidic acid derive.
R1(CH2)nCH2C(O)XCH2CH(OH)CH2OP(O)(OH)2 (R1 = C6-24 alkyl, alkenyl, alkynyl; X = O, NH; n = 0-12) stimulate bone formation and are useful for treatment of various metabolic disorders of bone such as osteoporosis. Thus, exposure of primary osteoblasts from

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2001 ACS (Continued)
fetal rat calvaria to 2-hydroxy-3-phosphonooxypropyl L-.alpha.-cis-9-octadecenoate (I) for 24 h stimulated DNA formation to 253% of the control value. I was prepd. in 7 steps from oleoyl chloride and 2,2-dimethyl-4-hydroxymethyldioxolane.
IT 222407-05-8P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel osteoblast-specific mitogens for treatment of metabolic disorders of bone)
RN 222407-05-8 CAPLUS
CN 9-Octadecenamide, N-[2-hydroxy-3-(phosphonooxy)propyl]-, (9Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 7
REFERENCE(S): (1) Cao, Y; PLANT PHYSIOL 1990, V94(3), P1199 CAPLUS
(2) Laboratorios Menarini S A; WO 9428004 A CAPLUS
(3) Moolenaar, W; JOURNAL OF BIOLOGICAL CHEMISTRY 1995, V270(22), P12949 CAPLUS
(4) Ortho Pharmaceutical Corp; EP 0524023 A CAPLUS
(5) Siddiqui, R; CELL SIGNALLING 1996, V8(5), P349 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1995:988373 CAPLUS
DOCUMENT NUMBER: 124:81473
TITLE: Surfactant-enhanced light emission- or absorbance-based binding assays for polynucleic acids
INVENTOR(S): Kidwell, David A.
PATENT ASSIGNEE(S): United States Dept. of the Navy, USA
SOURCE: U.S., 23 pp. Cont.-in-part of U.S. 5,332,659.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5466578	A	19951114	US 1994-280537	19940726
US 5314802	A	19940524	US 1992-865526	19920409
US 5332659	A	19940726	US 1993-4009	19930115

PRIORITY APPLN. INFO.: US 1992-865526 19920409
US 1993-4009 19930115
AB The fluorescence of polycyclic arom. labels, and excimers of these labels, attached to nucleic acids is greatly enhanced by the presence of quaternary ammonium surfactants having at least one long chain (C4 or greater) alkyl group. This enhancement may be advantageously used in Pi Overlapping Rings Systems Contained in a Homogeneous Assay (PORSCHA) and in conventional assays.
IT 172465-87-1
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(surfactant-enhanced light emission- or absorbance-based binding assays for polynucleic acids)
RN 172465-87-1 CAPLUS
CN 1-Pyrenebutanamide, N-[6-[[2-hydroxy-3-(phosphonooxy)propyl]amino]-6-oxohexyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1991:585787 CAPLUS
DOCUMENT NUMBER: 115:185787
TITLE: Preparation of hydroxypropoxylated phosphate ester salt surfactants
INVENTOR(S): Klopotek, Alojzy; Klopotek, Beata B.
PATENT ASSIGNEE(S): Instytut Chemii Przemyslowej, Pol.
SOURCE: Pol., 12 pp. Abstracted and indexed from the unexamined appl.
CODEN: POXXA7
DOCUMENT TYPE: Patent
LANGUAGE: Polish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PL 151315	B1	19900831	PL 1987-265243	19870417

OTHER SOURCE(S): MARPAT 115:185787
AB The title surfactants [R[CH2CH(OH)CH2O]n]kPO(OM)3-k [M = H, alkali metal, NH4, monoethanolammonium, diethanolammonium, triethanolammonium; R = R1O, R2O(CmH2m)z, R2O(CH2CH2O)r(CH2CH2CH2O)p, R3NH, R3N, R3NH(CmH2mO)z, R3N[(CmH2mO)x]2, R3CO2, R3CONH, R3CON, R3CONHCH2CH2O, R3CONH(CH2CH2O)z, R3CON(CH2CH2O)2, R3CON[(CH2CH2O)x]2; R1 = C1-36 alkyl, C8-36 hydroxyalkyl, C8-42 alkylaryl; R2 = C1-24 (hydroxy)alkyl, C7-42 alkylaryl; R3 = C4-36 (hydroxy)alkyl; k = 1, 2; m = 2-4; n = 1-100; p = 1-40; r = 1-30; x = 1-25; z = 1-30] are prepd. by reacting RHk in an anhyd. medium with glycidyl alc. (I), esterifying with P2O5 or P2O5 dissolved in H3PO4, and neutralizing with an alkali metal hydroxide, NH4OH, ethanolamine, diethanolamine, or triethanolamine. Thus, 3 mol 1-docosanol was reacted with 6 mol I at <373 K under an inert atm., 1 mol P2O5 added at .ltoreq.393 K, the mixt. cooled below 322 K, and 45% NaOH soln. added. The product consisted of 1 mol of n-C22H45O[CH2CH(OH)CH2O]3PO(ONa)3 and 1 mol [n-C22H45O[CH2CH(OH)CH2O]3]2PO(ONa). The yield was >98%.
IT 135804-09-0P
RL: PREP (Preparation)
(manuf. of, as anionic surfactant)
RN 135804-09-0 CAPLUS
CN Octadecanamide, N-[2-hydroxy-3-(phosphonooxy)propyl]-, compd. with 2-aminoethanol (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 135804-08-9
CMF C21 H44 N O6 P